BridgeBio Pharma (BBIO) Operating Leases (2020 - 2026)

BridgeBio Pharma has reported Operating Leases for 7 years, with the latest figure at $14.2 million in Q1 2026.

• Quarterly Operating Leases rose 189.24% year-over-year to $14.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.2 million (up 189.24% YoY) and the FY2025 annual result came in at $3.8 million, down 18.85% from the prior year.
• Operating Leases grew to $14.2 million in Q1 2026 per BBIO's latest filing, from $3.8 million in the prior quarter.
• Over five years, Operating Leases peaked at $15.5 million in Q1 2022 and troughed at $3.8 million in Q4 2025.
• A 5-year average of $9.3 million and a median of $9.0 million in 2023 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2024 and 2026: Operating Leases sank 47.71% in 2024, then jumped 189.24% in 2026.
• Over 5 years, Operating Leases stood at $12.3 million in 2022, then retreated by 26.83% to $9.0 million in 2023, then sank by 47.71% to $4.7 million in 2024, then retreated by 18.85% to $3.8 million in 2025, then soared by 273.03% to $14.2 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $14.2 million, $3.8 million, and $8.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.